Illumina (ILMN) Receives a Buy from Piper Jaffray

By Jason Carr

In a report released today, William Quirk from Piper Jaffray maintained a Buy rating on Illumina (ILMNResearch Report), with a price target of $341.00. The company’s shares closed last Monday at $284.48.

According to, Quirk is a 5-star analyst with an average return of 16.2% and a 62.3% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Edwards Lifesciences, and Pacific Biosciences.

Illumina has an analyst consensus of Strong Buy, with a price target consensus of $338.25, representing a 13.2% upside. In a report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $350.00 price target.

See today’s analyst top recommended stocks >>

Illumina’s market cap is currently $46.38B and has a P/E ratio of 50.11. The company has a Price to Book ratio of 10.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE).